Initial Experience With Tafamidis Treatment for Transthyretin Amyloid Cardiomyopathy

Background: Transthyretin amyloid cardiomyopathy is a progressive disease with a poor prognosis. There had been no specific treatment for transthyretin amyloid cardiomyopathy until tafamidis received expanded approval in March 2019 in Japan. However, the clinical efficacy of tafamidis remains unknow...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Circ Rep
Asıl Yazarlar: Nakamura, Makiko, Imamura, Teruhiko, Hori, Masakazu, Ushijima, Ryuichi, Joho, Shuji, Kinugawa, Koichiro
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: The Japanese Circulation Society 2020
Konular:
Original article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7819654/
https://ncbi.nlm.nih.gov/pubmed/33693263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1253/circrep.CR-20-0062
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller